高级别滤泡细胞来源的非间变性甲状腺癌:侵袭范围与突变谱和肿瘤学结局的相关性
这项单中心回顾性队列研究纳入1986至2020年接受手术的252例高级别滤泡细胞来源的非间变性甲状腺癌(HGFCTC)患者,按侵袭范围分为5个亚组。结果显示包膜内非侵袭和微侵袭肿瘤无区域或远处转移且5年疾病特异性生存率为100%,而浸润性肿瘤转移多、生存差;浸润性肿瘤以BRAFV600E驱动为主,包膜血管侵袭性肿瘤以NRAS驱动为主,包膜内非侵袭肿瘤以DICER1突变为主。
要点
- 浸润性肿瘤T3/T4期占71%、区域转移55%、远处转移25%,均显著高于其他亚组(p≤0.003)。
- 5年疾病特异性生存率:浸润性67.7%,包膜血管侵袭局灶90.4%、广泛88.1%,包膜内非侵袭/微侵袭100%(p=0.0002)。
- 浸润性肿瘤以BRAFV600E驱动为主,包膜血管侵袭性以NRAS驱动为主,包膜内非侵袭以DICER1突变为主。
核心结论
- HGFCTC由临床行为不同的亚组构成,其行为由血管侵袭范围和浸润程度决定。
- 包膜内非侵袭和微侵袭肿瘤的复发与生存结局极好,浸润性肿瘤则较差。
- 浸润性肿瘤 largely 为「BRAF样」,包膜血管侵袭性肿瘤为「RAS样」。
- 包膜内非侵袭肿瘤具有独特的分子谱,以DICER1突变为主且缺乏BRAFV600E突变。
研究设计与样本
- 单中心、回顾性队列研究,纳入1986至2020年因HGFCTC接受手术的252例患者。
- 将HGFCTC及相关实体「包膜内非侵袭性滤泡细胞高级别特征肿瘤」分为5个亚组:A包膜内非侵袭、B仅包膜侵袭(微侵袭)、C包膜血管侵袭伴局灶血管侵袭、D包膜血管侵袭伴广泛血管侵袭、E浸润性肿瘤。
- 117/252例患者可行MSK-IMPACT二代测序以分析突变谱差异。
主要发现
- 队列构成:浸润性50%、包膜血管侵袭性33%、包膜内非侵袭/微侵袭18%。
- 包膜内非侵袭或微侵袭患者就诊时无区域或远处转移。
- 浸润性肿瘤患者更常见T3/T4期(71%)、区域转移(55%)和远处转移(25%)(p≤0.003)。
- 5年疾病特异性生存率:浸润性67.7%,包膜血管侵袭局灶90.4%,包膜血管侵袭广泛88.1%,包膜内非侵袭/微侵袭100%(p=0.0002)。
- 常见突变为TERT(42%)、BRAFV600E(29%)、NRAS(27%)、EIF1AX(11%)、TP53(9%);通路改变包括RTK/RAS/RAF/MAPK(69%)、PI3K/AKT/MTOR(14%)、组蛋白甲基转移酶(9%)、SWI/SNF染色质重塑复合物(8%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The 2022 World Health Organization classification introduced the term high-grade follicular cell-derived nonanaplastic thyroid carcinoma (HGFCTC) to define invasive/infiltrative nonanaplastic thyroid carcinoma with high-grade features, including poorly differentiated thyroid carcinoma and high-grade differentiated thyroid carcinoma. Our objectives were to compare clinicopathological characteristics, oncologic outcomes, and mutation profiles among HGFCTC subgroups to better inform prognostication and treatment. Methods: In this single-center, retrospective cohort study of 252 patients who had surgery for HGFCTC from 1986 to 2020, we categorized HGFCTC and its related entity, "encapsulated noninvasive neoplasms of follicular cells with high-grade features," into five subgroups: (A) encapsulated noninvasive, (B) encapsulated with capsular invasion only (minimally invasive), (C) encapsulated angioinvasive with focal vascular invasion (VI), (D) encapsulated angioinvasive with extensive VI, and (E) infiltrative tumors. Next-generation sequencing with Memorial Sloan Kettering Cancer Center-Integrated Mutation Profiling of Actionable Cancer Targets was available for 117/252 patients to investigate differences in mutation profiles. Results: The cohort comprised 50% infiltrative, 33% encapsulated angioinvasive, and 18% encapsulated noninvasive/minimally invasive tumors. No patients with encapsulated noninvasive or minimally invasive disease had regional or distant metastases at presentation. Patients with infiltrative tumors were significantly more likely to present with T3/T4 disease (71%), regional metastases (55%), and distant metastases (25%) (p ≤ 0.003). Five-year disease-specific survival was poorer in patients with infiltrative disease (67.7%), compared to encapsulated angioinvasive focal VI (90.4%), encapsulated angioinvasive extensive VI (88.1%), and encapsulated noninvasive/minimally invasive (100%) (p = 0.0002) subgroups. Common mutations were TERT (42%), BRAFV600E (29%), NRAS (27%), EIF1AX (11%), and TP53 (9%). Pathways altered included RTK/RAS/RAF/MAPK (69%), PI3K/AKT/MTOR (14%), histone methyltransferases (9%), and SWI/SNF chromatin remodeling complex (8%). Subgroup analysis showed the infiltrative subgroup was mainly BRAFV600E-driven, and the encapsulated angioinvasive and minimally invasive subgroups were NRAS-driven. Encapsulated noninvasive tumors had a different mutation profile, with DICER1 as the main driver mutation. Conclusions: HGFCTC comprises different subgroups with different clinical behaviors determined by the extent of vascular invasion and degree of infiltration. Excellent recurrence and survival outcomes occur in encapsulated noninvasive and minimally invasive tumors compared to infiltrative tumors. Infiltrative tumors are largely "BRAF-like," whereas encapsulated angioinvasive tumors are "RAS-like." Encapsulated noninvasive tumors have a particularly unique molecular profile consisting of DICER1 mutations and a lack of BRAFV600E mutations.
引用
- Scholfield DW, Xu B, Levyn H, et al. High-Grade Follicular Cell-Derived Non-Anaplastic Thyroid Carcinoma: Correlating Extent of Invasion and Mutation Profile with Oncologic Outcome. Thyroid. 2025. PMID: 39761124. doi:10.1089/thy.2024.0499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。